S Zeuzem

Summary

Affiliation: Saarland University
Country: Germany

Publications

  1. ncbi request reprint The American Association For the Study of Liver Diseases: new perspectives in the treatment of hepatitis C
    Stefan Zeuzem
    Saarland University Hospital, Homburg, Saar, Germany
    Antivir Ther 11:267-71. 2006
  2. ncbi request reprint News in hepatitis C: Report from the 39th annual meeting of the European Association for the Study of the Liver
    Stefan Zeuzem
    Department of Internal Medicine II, Division of Gastroenterology, Hepatology and Endocrinology, Saarland University Hospital, Homburg Saar, Germany
    Antivir Ther 10:179-83. 2005
  3. ncbi request reprint Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    Gastroenterology 127:1724-32. 2004
  4. ncbi request reprint [Treatment of hepatitis C virus infection]
    S Zeuzem
    Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie und Endokrinologie, Universitatsklinikum des Saarlandes, Homburg, Saar
    Praxis (Bern 1994) 94:721-6. 2005
  5. ncbi request reprint Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C
    Stefan Zeuzem
    Klinik fur Innere Medizin II, Universitatskliniken des Saarlandes, 66421 Homburg Saar, Germany
    J Hepatol 39:106-11. 2003
  6. ncbi request reprint [Combination therapy for chronic viral hepatitis C]
    S Zeuzem
    Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie und Endokrinologie, Universitatskliniken des Saarlandes, Homburg Saar
    Dtsch Med Wochenschr 128:370-4. 2003
  7. ncbi request reprint International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    J Hepatol 43:250-7. 2005
  8. ncbi request reprint Pharmacokinetics of peginterferons
    Stefan Zeuzem
    Department of Medicine, Division of Gastroenterology, Hepatology, and Endocrinology, Saarland University Hospital, Homburg Saar, Germany
    Semin Liver Dis 23:23-8. 2003
  9. ncbi request reprint [Individualised treatment of chronic hepatitis C]
    S Zeuzem
    Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie, Endokrinologie, Diabetologie und Ernährungsmedizin, Universitatsklinikum des Saarlandes, 66 421 Homburg Saar
    Internist (Berl) 47:S20, S22-5. 2006
  10. ncbi request reprint [Difficult-to-treat patients with chronic hepatitis C]
    S Zeuzem
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar
    Praxis (Bern 1994) 95:1459-64. 2006

Collaborators

Detail Information

Publications128 found, 100 shown here

  1. ncbi request reprint The American Association For the Study of Liver Diseases: new perspectives in the treatment of hepatitis C
    Stefan Zeuzem
    Saarland University Hospital, Homburg, Saar, Germany
    Antivir Ther 11:267-71. 2006
  2. ncbi request reprint News in hepatitis C: Report from the 39th annual meeting of the European Association for the Study of the Liver
    Stefan Zeuzem
    Department of Internal Medicine II, Division of Gastroenterology, Hepatology and Endocrinology, Saarland University Hospital, Homburg Saar, Germany
    Antivir Ther 10:179-83. 2005
  3. ncbi request reprint Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    Gastroenterology 127:1724-32. 2004
    ....
  4. ncbi request reprint [Treatment of hepatitis C virus infection]
    S Zeuzem
    Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie und Endokrinologie, Universitatsklinikum des Saarlandes, Homburg, Saar
    Praxis (Bern 1994) 94:721-6. 2005
    ..Possibly, interferon-alpha also reduces the risk for patients with chronic hepatitis C to develop hepatocellular carcinoma...
  5. ncbi request reprint Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C
    Stefan Zeuzem
    Klinik fur Innere Medizin II, Universitatskliniken des Saarlandes, 66421 Homburg Saar, Germany
    J Hepatol 39:106-11. 2003
    ..Sensitive molecular tests may permit earlier determination of sustained virologic response following the completion of therapy in end-of-treatment responders...
  6. ncbi request reprint [Combination therapy for chronic viral hepatitis C]
    S Zeuzem
    Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie und Endokrinologie, Universitatskliniken des Saarlandes, Homburg Saar
    Dtsch Med Wochenschr 128:370-4. 2003
  7. ncbi request reprint International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    J Hepatol 43:250-7. 2005
    ..The aim of this study was to increase virologic response rates by individualized treatment according to the early virologic response...
  8. ncbi request reprint Pharmacokinetics of peginterferons
    Stefan Zeuzem
    Department of Medicine, Division of Gastroenterology, Hepatology, and Endocrinology, Saarland University Hospital, Homburg Saar, Germany
    Semin Liver Dis 23:23-8. 2003
    ..However, it remains unknown whether these differences in the initial viral decline predict differences in the primary clinical endpoint, sustained virological response...
  9. ncbi request reprint [Individualised treatment of chronic hepatitis C]
    S Zeuzem
    Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie, Endokrinologie, Diabetologie und Ernährungsmedizin, Universitatsklinikum des Saarlandes, 66 421 Homburg Saar
    Internist (Berl) 47:S20, S22-5. 2006
    ..A longer treatment duration of up to 72 weeks appears reasonable for HCV-1 infected patients with serum HCV RNA levels of 50-6,000 U/ml at week 12 of therapy...
  10. ncbi request reprint [Difficult-to-treat patients with chronic hepatitis C]
    S Zeuzem
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar
    Praxis (Bern 1994) 95:1459-64. 2006
    ..g. serotonine re-uptake inhibitors for depression, erythropoetin for ribavirin-associated anemia, etc.). In addition, optimisation of adherence and compliance is always mandatory...
  11. ncbi request reprint [Treatment of hepatitis B and C -- current standards]
    S Zeuzem
    Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie, Endokrinologie, Diabetologie und Ernährungsmedizin, Universitatsklinikum des Saarlandes, Homburg Saar
    Dtsch Med Wochenschr 129:S57-9. 2004
  12. ncbi request reprint First-phase parameters in hepatitis C viral kinetics
    Stefan Zeuzem
    Department of Medicine, Division of Gastroenterology, Hepatology, and Endocrinology, University Hospital Homburg Saar, Germany
    J Viral Hepat 9:332-3. 2002
  13. ncbi request reprint Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?
    Stefan Zeuzem
    Department of Internal Medicine II, Saarland University Hospital, Homburg Saar, Germany
    Ann Intern Med 140:370-81. 2004
    ..This article reviews the data on interferon-based therapies among patients with lower chances for sustained virologic response and discusses the potential of the new pegylated interferons...
  14. ncbi request reprint Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3
    Stefan Zeuzem
    Department of Medicine, Saarland University Hospital, Homburg Saar, Germany
    J Hepatol 40:993-9. 2004
    ..The aim of the present study was to investigate this schedule for HCV-2/3 infected patients in the era of pegylated interferon-alpha plus ribavirin...
  15. ncbi request reprint [Chronic hepatitis C virus infection: always treat!--Pro]
    S Zeuzem
    Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie und Endokrinologie, Universitatskliniken des Saarlandes, Germany
    Dtsch Med Wochenschr 127:1840. 2002
  16. ncbi request reprint Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    Stefan Zeuzem
    Clinic of Internal Medicine II, Department of Medicine, Saarland University Hospital, Kirrbergerstrasse, 66421 Homburg Saar, Germany
    J Hepatol 44:97-103. 2006
    ..The aim of the present study was to investigate this schedule in the era of pegylated interferon-alpha plus ribavirin...
  17. ncbi request reprint [Chronic hepatitis C: new perspectives in therapy]
    S Zeuzem
    Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie, Endokrinologie, Diabetologie und Ernährungsmedizin, Universitatsklinikum des Saarlandes, Homburg Saar
    Z Gastroenterol 42:363-4. 2004
  18. ncbi request reprint [Treatment of hepatitis C--update 2005]
    N Forestier
    Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie, Endokrinologie, Diabetologie und Ernährungsmedizin, Universitatsklinikum des Saarlandes
    Dtsch Med Wochenschr 130:S215-6. 2005
  19. ncbi request reprint Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity
    S Zeuzem
    Department of Internal Medicine, Saarland University Hospital, 66421 Homburg Saar, Germany
    Aliment Pharmacol Ther 24:1133-49. 2006
    ..These patients have historically remained untreated but substantial evidence indicates liver damage, progression of disease and impaired quality of life in some individuals...
  20. doi request reprint Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin
    A Potthoff
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    Scand J Gastroenterol 44:1487-90. 2009
    ..In contrast, a sustained response concerning HCV is durable. We recommend long-term monitoring of HBV/HCV-co-infected patients after IFN a-based therapies...
  21. ncbi request reprint Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon-alpha-based therapy in HCV-1b-infected patients
    M W Welker
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    J Viral Hepat 14:338-49. 2007
    ..Amino acid variations with relevant changes of physicochemical properties may influence replication efficiency, associated with a rapid early virological response...
  22. ncbi request reprint Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy
    Christoph Sarrazin
    Department of Internal Medicine, J W Goethe University Hospital, Frankfurt, Germany
    J Hepatol 52:832-8. 2010
    ..It is unknown whether shortening of treatment duration to 16/24 weeks in patients with rapid virological response at week 4 (RVR) and viral loads between 10 and 50IU/ml is possible...
  23. ncbi request reprint The kinetics of hepatitis C virus infection
    S Zeuzem
    Department of Medicine, Division of Gastroenterology and Hepatology, University of Frankfurt a M, Germany
    Clin Liver Dis 5:917-30. 2001
    ..Nonresponding patients typically show constant viremia or even a rebound during this second phase...
  24. ncbi request reprint Review article: predicting response in hepatitis C virus therapy
    U Mihm
    Department of Internal Medicine II, Saarland University, Homburg Saar, Germany
    Aliment Pharmacol Ther 23:1043-54. 2006
    ....
  25. ncbi request reprint SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders
    Christoph Sarrazin
    Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    Gastroenterology 132:1270-8. 2007
    ....
  26. ncbi request reprint Dynamics of hepatitis C virus quasispecies turnover during interferon-alpha treatment
    M von Wagner
    Innere Medizin II, Universitatskliniken des Saarlandes, Homburg Saar, Germany
    J Viral Hepat 10:413-22. 2003
    ..Thus, nonresponse to IFN cannot exclusively be explained by changes in the quasispecies...
  27. ncbi request reprint Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C
    B Kronenberger
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, 66421 Homburg Saar, Germany
    J Viral Hepat 12:307-14. 2005
    ....
  28. ncbi request reprint [Postexposure prevention after occupational exposure to HBV, HCV and HIV]
    U Sarrazin
    Klinik und Poliklinik fur Innere Medizin II, Universitatskliniken des Saarlandes, Homburg Saar, Germany
    Unfallchirurg 107:129-142. 2004
    ..PEP should be started as early as possible and carried out for 28 days. The recommended PEP consists of two inhibitors of the reverse transcriptase and one inhibitor of the protease...
  29. ncbi request reprint [Perspectives in hepatology in the next 2-3 years: what will be clinically relevant? Viral hepatitis]
    M Friedrich-Rust
    Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie, Endokrinologie, Diabetologie und Ernährungsmedizin, Universitatsklinikum des Saarlandes
    Dtsch Med Wochenschr 130:S229-30. 2005
  30. ncbi request reprint Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative diseases
    W P Hofmann
    Klinik fur Innere Medizin II, Kirrbergerstrasse, Universitatsklinikum des Saarlandes, Homburg, Germany
    J Viral Hepat 14:484-91. 2007
    ..005). Although HCV can induce BCL-6 mutations in vitro, lower mutational frequencies and decreased BCL-6 mRNA expression in vivo suggest no major role of aberrant somatic hypermutation in HCV-associated MC and B-NHL...
  31. ncbi request reprint Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C
    M Friedrich-Rust
    Department of Internal Medicine, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
    J Viral Hepat 16:168-77. 2009
    ....
  32. ncbi request reprint Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
    Christoph Sarrazin
    Klinik fur Innere Medizin II, Universitat des Saarlandes, Homburg Saar, Germany
    Gastroenterology 132:1767-77. 2007
    ..4A protease inhibitor, has shown strong antiviral activity in phase 1 clinical studies. Because of high levels of HCV replication and the low fidelity of HCV polymerase, selection of resistant isolates during therapy may occur...
  33. ncbi request reprint Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C
    Markus Cornberg
    Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, D 30625 Hannover, Germany
    J Hepatol 37:843-7. 2002
    ..The present study is a pilot study evaluating the efficacy and safety of combination therapy with interferon alfa-2a and MMF in interferon alfa nonresponder patients...
  34. ncbi request reprint Dynamics of hepatitis C virus infection
    Stefan Zeuzem
    Department of Medicine, University Hospital Homburg Saar, Germany
    Ann Hepatol 1:56-63. 2002
    ..This second phase decay is predictive for the virologic end-of-treatment and even more the sustained response. Non-responding patients typically show constant viremia or even a rebound during this second phase...
  35. ncbi request reprint Impaired health-related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels
    M von Wagner
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg, Saar, Germany
    J Viral Hepat 13:828-34. 2006
    ..No association of quality of life with severity of liver disease was found. Impairment of HRQOL by chronic infection with HCV is similar in patients with PNAL and those with elevated aminotransferase levels...
  36. ncbi request reprint Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression
    B Kronenberger
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    J Viral Hepat 11:310-8. 2004
    ....
  37. ncbi request reprint [Post-exposure prevention after occupational exposure to HBV, HCV and HIV]
    U Sarrazin
    Klinik und Poliklinik fur Innere Medizin II, Universitatskliniken des Saarlandes, Homburg Saar, Germany
    Orthopade 33:231-44. 2004
    ..PEP should be started as early as possible and carried out for 28 days. The recommended PEP consists of two inhibitors of the reverse transcriptase and one inhibitor of the protease...
  38. ncbi request reprint Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels
    Bernd Kronenberger
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Hepatology 40:1442-9. 2004
    ..These data show that virological response in patients with chronic hepatitis C is less associated with baseline ALT than with GGT levels...
  39. ncbi request reprint Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon
    Eva Herrmann
    Medizinische Klinik und Poliklinik, Innere Medizin II, Universitatskliniken des Saarlandes, Homburg Saar, Germany
    Hepatology 37:1351-8. 2003
    ..This finding suggests that combination treatment leads to a better restoration of the patient's immune response...
  40. ncbi request reprint Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy
    Wolf Peter Hofmann
    Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    Gastroenterology 132:921-30. 2007
    ..Ribavirin acts as an RNA virus mutagen in vitro, thereby leading to error catastrophe. However, data in CHC are controversial...
  41. ncbi request reprint Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
    Michael von Wagner
    Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Gastroenterology 129:522-7. 2005
    ..Whether shorter treatment durations are possible for these patients without compromising sustained virologic response rates is unknown...
  42. doi request reprint Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study
    I Blumenstein
    First Department of Internal Medicine, Division of Gastroenterology, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    J Crohns Colitis 5:203-10. 2011
    ..The aim of the present study was to evaluate gender-related differences in the treatment of a distinct IBD patient population treated in the Rhein-Main region, Germany...
  43. ncbi request reprint [Postexposure prophylaxis after occupational exposure to HBV, HCV and HIV]
    U Sarrazin
    Klinik und Poliklinik für Innere Medizin, Universitatskliniken des Saarlandes, Homburg Saar, Germany
    Radiologe 44:181-94. 2004
    ..PEP should be started as early as possible and carried out for 28 days. The recommended PEP consists of two inhibitors of the reverse transcriptase and one inhibitor of the protease...
  44. ncbi request reprint GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection
    Christoph Sarrazin
    Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin II, Kirrberger Str 41, D 66421 Homburg Saar, Germany
    J Hepatol 43:388-93. 2005
    ..The G protein beta3 subunit (GNB3) C825T polymorphism has been shown to determine immune cell functions in vitro. We investigated the association of GNB3 genotypes with treatment response in HCV-infected patients...
  45. ncbi request reprint Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C
    Ulrike Mihm
    Klinik fur Innere Medizin II, Universitatskliniken des Saarlandes, Kirrberger Strasse, D 66421 Homburg Saar, Germany
    J Hepatol 40:845-52. 2004
    ..The clinical significance of interleukin-8 levels for virologic response to interferon-alpha-based treatment in patients with chronic hepatitis C is unknown...
  46. ncbi request reprint [Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists]
    W P Hofmann
    Universitatsklinikum des Saarlandes, Kirrberger Strasse, 66421 Homburg Saar
    Z Gastroenterol 44:25-31. 2006
    ..The presented network allows characterization of the treatment outcome in chronic hepatitis C not only with regard to virus- and host-related factors but also on an individual physician basis...
  47. doi request reprint Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy
    C M Lange
    Department of Medicine, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Aliment Pharmacol Ther 32:14-28. 2010
    ..Novel, directly acting anti-viral agents, also named 'specifically targeted anti-viral therapy for hepatitis C' (STAT-C) compounds, are currently under development...
  48. ncbi request reprint Interleukin-18 is increased only in a minority of patients with active Crohn's disease
    C Schmidt
    Department of Internal Medicine II, Saarland University, Homburg, Germany
    Int J Colorectal Dis 22:1013-20. 2007
    ..Therefore, we investigated the IL-18/IL-18 bp system in a large group of patients with active inflammatory bowel disease (IBD) to identify patients that could respond theoretically to IL-18 neutralizing treatment strategies...
  49. ncbi request reprint Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
    Nicole Forestier
    Saarland University Hospital, Homburg, Germany
    Hepatology 46:640-8. 2007
    ....
  50. ncbi request reprint Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C
    Ulrike Mihm
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Kirrberger Str, 66421 Homburg Saar, Germany
    Antivir Ther 11:507-19. 2006
    ..The relevance of HCV p7 amino acid (aa) variations for response to antiviral therapy with amantadine is unknown...
  51. ncbi request reprint Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a
    Huub C Gelderblom
    Department of Gastroenterology and Hepatology, AMC Liver Center, Homburg Saar, Germany
    Scand J Gastroenterol 43:1122-7. 2008
    ..4A protease inhibitor telaprevir (VX-950), with or without peginterferon alfa-2a (Peg-IFN)...
  52. ncbi request reprint Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy
    Wolf Peter Hofmann
    Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin II, Homburg Saar, Germany
    J Clin Virol 32:86-91. 2005
    ..For the NS5A protein, mutations within the interferon sensitivity determining region (ISDR) and the complete NS5A protein may be of importance for response to interferon alpha-based treatment in patients infected with HCV subtype 1a/b...
  53. doi request reprint The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection
    Andrej Potthoff
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    J Hepatol 49:688-94. 2008
    ..The efficacy of pegylated interferon alpha and ribavirin in HBV/HCV co-infected patients is unknown...
  54. doi request reprint Modulation of replication efficacy of the hepatitis C virus replicon Con1 by site-directed mutagenesis of an NS4B aminoterminal basic leucine zipper
    M W Welker
    Klinikum der Johann Wolfgang Goethe Universitat, Medizinische Klinik, Theodor Stern Kai, Frankfurt am Main, Germany
    J Viral Hepat 19:775-83. 2012
    ..RNA replication efficacy can be modulated by site-directed mutagenesis at specific bZIP functional sites. New adaptive amino acid mutations were identified within the HCV NS4B protein...
  55. doi request reprint MUTYH hotspot mutations in unselected colonoscopy patients
    M Casper
    Department of Medicine II, Saarland University Medical Centre, Homburg, Germany
    Colorectal Dis 14:e238-44. 2012
    ..Y179C and p.G396D account for the majority of pathogenic variants of MUTYH in Caucasians. Our aim was to evaluate the prevalence of MUTYH mutations in a prospective cohort of unselected patients with different colorectal diseases...
  56. ncbi request reprint Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061
    Eva Herrmann
    Medizinische Klinik und Poliklinik, Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Antivir Ther 11:371-6. 2006
    ..Estimates of viral clearance and infected-cell loss support conclusions on these rates and on treatment mechanisms from previous studies on interferon-alpha-based treatments...
  57. doi request reprint Interferon-based therapy for chronic hepatitis C: current and future perspectives
    Stefan Zeuzem
    Department of Medicine, JW Goethe University Hospital, Frankfurt, Germany
    Nat Clin Pract Gastroenterol Hepatol 5:610-22. 2008
    ..These compounds will be used, at least initially, in combination with peginterferon alpha plus ribavirin, extending the pivotal role of interferon-based therapy in the management of chronic hepatitis C...
  58. ncbi request reprint Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entity
    C Schmidt
    Department of Internal Medicine II, Saarland University Hospital, Homburg Saar, Germany
    Int J Colorectal Dis 21:419-26. 2006
    ..Therefore, we characterized cytokine and chemokine transcripts in inflamed and non-inflamed pouches in patients with UC compared to those with FAP and Crohn's disease (CD)...
  59. ncbi request reprint Response predictors and results of a long-term treatment with lamivudine in patients with chronic hepatitis B
    U Mihm
    Klinik und Poliklinik fur Innere Medizin II, Universitatskliniken des Saarlandes, Kirrberger Str, 66421 Homburg Saar
    Z Gastroenterol 41:249-54. 2003
    ..Patients and methods : 39 patients (17 HBeAg+, 22 HBeAg-) were treated with lamivudine for a median duration of 2.5 years (range: 0.5-4). Outcome to therapy and predictors for response and drug resistance were analyzed retrospectively...
  60. ncbi request reprint [Standard treatment of acute and chronic hepatitis C]
    S Zeuzem
    Medizinische Klinik und Poliklinik Innere Medizin II, Universitatskliniken des Saarlandes, Homburg
    Z Gastroenterol 42:714-9. 2004
  61. ncbi request reprint Downregulation of CD44v6 in colorectal carcinomas is associated with hypermethylation of the CD44 promoter region
    A Stallmach
    Department of Internal Medicine II, Saarland University, Homburg Saar, Germany
    Exp Mol Pathol 74:262-6. 2003
    ..05). These results demonstrated that methylation of the 5'CpG island of the CD44 gene is closely associated with decreased expression of CD44v6 in human colorectal carcinomas...
  62. ncbi request reprint [Generalized hyperpigmentation and malignant acanthosis nigricans. A case of a patient with hereditary hemochromatosis and gastric cancer]
    A Kalt
    Klinik für Dermatologie Venerologie und Allergologie, Universitätsklinikum des Saarlandes Homburg Saar
    Hautarzt 56:581-5. 2005
    ..Simultaneous manifestation of hyperpigmentation as a result of hemochromatosis as well as malignant acanthosis nigricans as a paraneoplastic symptom in gastric cancer is very rare...
  63. ncbi request reprint Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection
    Christoph Sarrazin
    Klinik fur Innere Medizin II, Universitat des Saarlandes, Homburg Saar, Germany
    J Infect Dis 192:1710-9. 2005
    ..Mutations in nonstructural (NS) hepatitis C virus (HCV) proteins enhance replication in HCV-1a/b replicons. The prevalence of such mutations and their clinical significance in vivo are unknown...
  64. ncbi request reprint Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C
    Heiner Wedemeyer
    Department of Gastroenterology, Hepatology, and Endocrinology, Medical University of Hannover, Germany
    Vaccine 27:5142-51. 2009
    ..Optimized vaccine responses may enhance sustained virologic response rates obtained with standard treatment of chronic hepatitis C...
  65. ncbi request reprint The kinetics of hepatitis C virus
    Eva Herrmann
    Saarland University, Faculty of Medicine, Internal Medicine II, Homburg Saar, Germany
    Eur J Gastroenterol Hepatol 18:339-42. 2006
    ..The main aims of analysing hepatitis C viral kinetics include the efficient comparison of different treatment regimens, prediction of virological response, and conclusions on antiviral mechanisms of therapy...
  66. pmc Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5
    Christoph Sarrazin
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Kirrberger Str, D 66421 Homburg Saar, Germany
    J Clin Microbiol 44:729-37. 2006
    ..For the HPS/CTM assay, a significant underestimation of the HCV RNA concentrations of genotypes 2a/c, 3, 4, and 5 was observed. For the bDNA assay, a constant lower quantification of genotypes 1 to 3 was detected...
  67. ncbi request reprint DNA mismatch repair and Lynch syndrome
    Guido Plotz
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Kirrberger Strasse, Gebäude 41, D 66421 Homburg, Germany
    J Mol Histol 37:271-83. 2006
    ..We review the biochemistry of mismatch repair and also introduce the clinical, diagnostic and genetic aspects of Lynch syndrome...
  68. ncbi request reprint Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy
    Jorg Bojunga
    Internal Medicine II, Saarland University Hospital, Kirrberger Strasse, 66421 Homburg Saar, Germany
    World J Gastroenterol 12:5875-7. 2006
    ..To investigate plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), an established marker of cardiac function, in patients with chronic hepatitis C during interferon-based antiviral therapy...
  69. ncbi request reprint Analysis of the human MutLalpha.MutSalpha complex
    Guido Plotz
    University of the Saarland, Klinik fur Innere Medizin II, Homburg Saar, Germany
    Biochem Biophys Res Commun 340:852-9. 2006
    ..The described conditions likely capture an intermediate of the repair reaction which has bound ATP and ADP in the two nucleotide-binding sites of MutSalpha...
  70. ncbi request reprint Current therapy for hepatitis C
    Mireen Friedrich-Rust
    Department of Internal Medicine, Saarland University Hospital, Kirrbergerstr, Bldg 41, 66421 Homburg Saar, Germany
    Int J Colorectal Dis 22:341-9. 2007
    ..The duration of therapy depends on the HCV genotype with currently 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3...
  71. ncbi request reprint Tumor regression by combination antisense therapy against Plk1 and Bcl-2
    Robert Elez
    Department of Internal Medicine, Johann Wolfgang Goethe University, Frankfurt, Germany
    Oncogene 22:69-80. 2003
    ..This study provides evidence that combined systemic administration of antisense ODNs against proliferation and pro- survival associated targets and in vivo electroporation of tumors represents a promising antitumor therapeutic approach...
  72. pmc Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses
    Christoph Sarrazin
    Medizinische Klinik II, Johann Wolfgang Goethe Universitat, 60590 Frankfurt am Main, Germany
    J Virol 76:11079-90. 2002
    ..For improvement of mutational analysis, a refined specific functional data test procedure is proposed...
  73. ncbi request reprint Protein kinase A mediates cAMP-induced tyrosine phosphorylation of the epidermal growth factor receptor
    Albrecht Piiper
    Department of Internal Medicine, University of Saarland, D 66421, Homburg Saar, Germany
    Biochem Biophys Res Commun 301:848-54. 2003
    ..While PKA may directly phosphorylate the EGFR on serine residues, PKA-induced tyrosine phosphorylation of the EGFR occurs by an indirect mechanism...
  74. ncbi request reprint Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy
    Ulrike Mihm
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Kirrberger Str, 66421 Homburg Saar, Germany
    J Hepatol 43:217-24. 2005
    ..Mathematical analysis of viral kinetics during lamivudine-adefovir combination therapy has not yet been performed in patients with lamivudine-resistant hepatitis B...
  75. ncbi request reprint Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon
    Albrecht Piiper
    Department of Internal Medicine II, University of the Saarland, D 66421 Homburg Saar, Germany
    J Biol Chem 278:7065-72. 2003
    ....
  76. ncbi request reprint Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients
    Wolf Peter Hofmann
    Innere Medizin II, Medizinische Klinik und Poliklinik, Universitat des Saarlandes, Homburg, Germany
    J Infect Dis 187:982-7. 2003
    ..9; range, 1-5) or those who did not respond (2.8; range, 1-5) (P = .041). However, when the same analyses were based only on functionally nonconserved mutations, no significant differences were observed...
  77. ncbi request reprint Development of ulcerative colitis after heart transplantation during immunosuppressive therapy
    B Jungling
    Department of Internal Medicine II, Saarland University, Germany
    Z Gastroenterol 43:195-9. 2005
    ..Cardiac transplantation has become an accepted treatment modality for end-stage heart failure. Immunosuppressive agents, which are used after transplantation, are considered as therapeutic options for inflammatory bowel disease...
  78. ncbi request reprint Pertussis toxin inhibits cholecystokinin- and epidermal growth factor-induced mitogen-activated protein kinase activation by disinhibition of the cAMP signaling pathway and inhibition of c-Raf-1
    A Piiper
    Department of Internal Medicine, Johann Wolfgang Goethe University, Frankfurt, Germany
    Mol Pharmacol 58:608-13. 2000
    ....
  79. pmc Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells
    Simone Kiermayer
    Department of Internal Medicine, University of Saarland, D 66421 Homburg Saar, Germany
    Mol Biol Cell 16:5639-48. 2005
    ..Thus, the present study showed that the outcome of cAMP signaling can depend heavily on the set of cAMP effectors activated...
  80. ncbi request reprint Antioxidative treatment reverses imbalances of nitric oxide synthase isoform expression and attenuates tissue-cGMP activation in diabetic rats
    Jorg Bojunga
    Innere Medizin II, Medizinische Klinik und Poliklinik, Saarland University, Homburg Saar, Germany
    Biochem Biophys Res Commun 316:771-80. 2004
    ..Furthermore, our data show that antioxidative treatment is capable of reversing changes in the NO-cGMP system and may therefore be an important therapeutic option for preventing vascular damage in diabetes mellitus...
  81. ncbi request reprint The way forward in HCV treatment--finding the right path
    Michael P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany
    Nat Rev Drug Discov 6:991-1000. 2007
    ..Here we review the specific challenges posed by HCV, and recent developments in the design of vaccines and novel antiviral agents...
  82. pmc Mutations in the MutSalpha interaction interface of MLH1 can abolish DNA mismatch repair
    Guido Plotz
    Klinik fur Innere Medizin II, Gebäude 41 Kirrberger Strasse, Universitat des Saarlandes, D 66421 Homburg Saar, Germany
    Nucleic Acids Res 34:6574-86. 2006
    ....
  83. ncbi request reprint Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RT-PCR) for detection of hepatitis C virus RNA in liver tissue
    Wolf Peter Hofmann
    Klinik fur Innere Medizin II, Universitat des Saarlandes, 66421 Homburg, Germany
    J Clin Virol 32:289-93. 2005
    ..It is unknown whether the higher sensitivity of TMA in comparison with polymerase chain reaction (PCR)-based assays is related to a higher efficiency of the extraction and/or amplification step...
  84. ncbi request reprint Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection
    Mireen Friedrich-Rust
    Department of Internal Medicine, Saarland University Hospital, Homburg Saar, Germany
    Ultrasound Med Biol 33:1362-7. 2007
    ....
  85. ncbi request reprint RNAse A-like enzymes in serum inhibit the anti-neoplastic activity of siRNA targeting polo-like kinase 1
    Jorg Haupenthal
    Department of Internal Medicine II, University of Saarland, Homburg, Saar, Germany
    Int J Cancer 121:206-10. 2007
    ..This loss of anti-neoplastic activity can be prevented by inhibition of their degradation by RNAse A-like enzymes. This may have important implications for the development of a human therapeutic application of siRNAs...
  86. ncbi request reprint BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors
    Nikolaus Lubomierski
    2nd Department of Internal Medicine, Saarland University Hospital, Homburg Saar, Germany
    Cancer 104:952-61. 2005
    ..These alterations were attributed to defective DNA mismatch repair, which underlies MSI. It was the objective of this study to clarify the role of BRAF in colorectal carcinoma with MSI...
  87. ncbi request reprint Involvement of the platelet-derived growth factor receptor in angiotensin II-induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells
    U F Mondorf
    Department of Medicine, Division of Nephrology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany
    FEBS Lett 472:129-32. 2000
    ..In conclusion, our data show that Ang II-induced activation of mitogenic signalling cascade in human mesangial cells involves ligand-independent activation of the PDGFR, but not of the coexpressed EGFR...
  88. ncbi request reprint Hepatitis C viral kinetic models
    E Herrmann
    Department of Medicine, Saarland University Hospital, Germany
    Cell Death Differ 10:S7-8. 2003
  89. ncbi request reprint Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study
    Johannes Wiegand
    Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany
    Hepatology 43:250-6. 2006
    ..The high number of dropouts underlines the importance of thorough patient selection and close monitoring during therapy. Thus, future studies should identify factors predicting spontaneous viral clearance to avoid unnecessary therapy...
  90. doi request reprint Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis
    Kalliopi Zachou
    Department of Gastroenterology, Hepatology and Endocrinology, Hanover Medical School, Hanover, Germany
    Liver Int 30:430-7. 2010
    ..ii) Biochemical parameters did not accurately indicate the stage and grade of liver disease in chronic HDV and thus liver biopsy seems to remain the major tool for the evaluation of delta hepatitis patients...
  91. ncbi request reprint Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum
    Jorg Haupenthal
    Department of Internal Medicine II, University of Saarland, D 66421 Homburg Saar, Germany
    Biochem Pharmacol 71:702-10. 2006
    ..These findings might be of great importance for a possible future human therapeutic application of siRNAs...
  92. ncbi request reprint Absence of the interstitial cell of Cajal network in mitochondrial neurogastrointestinal encephalomyopathy
    V Zimmer
    Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    Neurogastroenterol Motil 21:627-31. 2009
    ....
  93. ncbi request reprint Receptor tyrosine kinases are signaling intermediates of G protein-coupled receptors
    A Piiper
    Department of Internal Medicine II, University of Saarland, D 66421 Homburg Saar, Germany
    Curr Pharm Des 10:3539-45. 2004
    ..This review focuses on the mechanisms how GPCRs and intracellular messengers elicit transactivation of different RTKs and the resulting different biological responses...
  94. ncbi request reprint Structural and functional comparison of the non-structural protein 4B in flaviviridae
    Christoph Welsch
    Internal Medicine II, Saarland University Hospital, Kirrberger Strasse, 66421 Homburg Saar, Germany
    J Mol Graph Model 26:546-57. 2007
    ..Important structural and functional properties of NS4B are predicted with implications for ER-stress response, altered gene expression and replication efficacy...
  95. ncbi request reprint Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C
    Bernd Kronenberger
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Kirrberger Strasse, D 66421 Homburg Saar, Germany
    J Leukoc Biol 80:298-308. 2006
    ..033). Lymphocyte subsets show different patterns of CD81 response before and during antiviral treatment, which are associated with administration of IFN-alpha and antiviral response...
  96. ncbi request reprint Overview of commercial HBV assays systems
    Stefan Zeuzem
    Department of Internal Medicine II, University Hospital, Homburg Saar, Germany
    Methods Mol Med 95:3-13. 2004
  97. ncbi request reprint Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis
    Carsten Schmidt
    Department of Internal Medicine II, Saarland University, Homburg, Germany
    Inflamm Bowel Dis 11:16-23. 2005
    ..IL-27 consists of EBI3, an IL-12p40-related protein, and p28, a newly discovered IL-12p35-related polypeptide...
  98. ncbi request reprint Molecular detection of thyroid cancer: an update
    Jorg Bojunga
    Department Internal Medicine II, Endocrinology, Saarland University Hospital, Homburg Saar, Germany
    Clin Endocrinol (Oxf) 61:523-30. 2004
  99. ncbi request reprint Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
    Stefan Zeuzem
    JW Goethe University Hospital, Frankfurt, Germany
    Antivir Ther 13:747-60. 2008
    ..The treatment paradigm for chronic hepatitis C continues to evolve and will eventually incorporate new drugs as they are approved...
  100. ncbi request reprint Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
    Bart J Veldt
    Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Ann Intern Med 147:677-84. 2007
    ..Clinical outcomes of chronic hepatitis C infection in patients with advanced fibrosis include liver failure, hepatocellular carcinoma, and death...
  101. doi request reprint Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy
    Paolo Pugnale
    Department of Pathology and Immunology, University of Geneva Medical Center, 1211 Geneva, Switzerland
    J Hepatol 48:932-8. 2008
    ..Analysis of hepatitis C virus (HCV) RNA kinetics in compartments other than plasma may help in understanding HCV replication and identifying clinically significant patterns of treatment response...